Risks of combining immunosuppressive and biological treatments in inflammatory bowel disease.
Roblin
Xavier
X
Phelip
Jean Marc
JM
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D000069285:Infliximab; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use*; D012307:Risk Factors; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D007155:Immunologic Factors; D007166:Immunosuppressive Agents; D000069285:Infliximab; D008727:Methotrexate